Risk of Hyperkalemia With Empagliflozin, Finerenone, or Both
Over 180 days, the combination of empagliflozin and finerenone did not significantly mitigate the risk of hyperkalemia. The treatment effect was maintained regardless of development of hyperkalemia. (Combination Effect of Finerenone and Empagliflozin in Participants with Chronic Kidney Disease and Type 2 Diabetes Using a Urinary Albumin-to-Creatinine Ratio Endpoint [CONFIDENCE]; NCT05254002).
Authors
- Amy K. Mottl (ORCID: https://orcid.org/0000-0002-4258-1726)
- Carolina Solis‐Herrera (ORCID: https://orcid.org/0000-0002-6215-9418)
- Jennifer B. Green (ORCID: https://orcid.org/0000-0002-9967-5352)
- Masaomi Nangaku (ORCID: https://orcid.org/0000-0001-7401-2934)
- Johannes F.E. Mann (ORCID: https://orcid.org/0000-0002-3154-5332)
- Julio Rosenstock (ORCID: https://orcid.org/0000-0001-8324-3275)
- Janet B. McGill (ORCID: https://orcid.org/0000-0002-6228-6521)
- Rajiv Agarwal (ORCID: https://orcid.org/0000-0001-8355-7100)
- Charlie Scott (ORCID: https://orcid.org/0000-0002-2816-4889)
- Muthiah Vaduganathan (ORCID: https://orcid.org/0000-0003-0885-1953)
- Carolina Aldworth
- Li Li (ORCID: https://orcid.org/0000-0003-0897-5374)
- Peter Rossing
- Hiddo J.L. Heerspink
- Meike Brinke
Institutions
- University of North Carolina at Chapel Hill (US)
- Brigham and Women's Hospital (US)
- University Medical Center Groningen (NL)
- Steno Diabetes Centers (DK)
- Harvard University (US)
- Bayer (United States) (US)
- The University of Texas at San Antonio Health Science Center (US)
- University of Groningen (NL)
- Duke University (US)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Washington University in St. Louis (US)
- Clinical Research Institute (US)
- Richard L. Roudebush VA Medical Center (US)
- Velocity Clinical Research (United States) (US)
- Indiana University – Purdue University Indianapolis (US)
- Bayer (Germany) (DE)
- The University of Tokyo (JP)
Publication Details
- Journal
- Journal of the American College of Cardiology
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.jacc.2025.10.049
- Citations
- 1
- Primary Topic
- Potassium and Related Disorders
- Type
- article
- Field-Weighted Citation Impact
- 1.52